Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 393 • 2013 ACR/ARHP Annual Meeting
Survival In Rheumatoid Arthritis Associated Pulmonary Arterial Hypertension Is Comparable To Idiopathic Pulmonary Arterial Hypertension
Saghar Sadeghi¹, John T. Granton², Pooneh Akhavan³ and Sindhu R. Johnson⁴, ¹Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ⁴Medicine, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada
Background/Purpose: To evaluate survival in rheumatoid arthritis associated pulmonary arterial hypertension (RA-PAH) compared to idiopathic PAH (IPAH) patients. Secondary outcomes included evaluation of differences in…
Abstract Number: 2684 • 2013 ACR/ARHP Annual Meeting
Impact Of Anti-Rheumatic Treatment On Immunogenicity Of Pandemic H1N1 Influenza Vaccine In Patients With Arthritis
Meliha C. Kapetanovic¹, Lars-Erik Kristensen², Tore Saxne³, Teodora Aktas⁴, Andreas Mörner⁴ and Pierre Geborek⁵, ¹Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ²Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden, ³Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Vaccinology Unit, Department of Diagnostics and Vaccinology, Swedish Institute for Communicable Disease Control, Solna, Sweden., Vaccinology Unit, Department of Diagnostics and Vaccinology, Swedish Institute for Communicable Disease Control, Solna, Sweden., Solna, Sweden, ⁵Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis Background/Purpose: An adjuvanted pandemic H1N1 influenza (pH1N1) vaccine (Pandemrix®) was…
Abstract Number: 2304 • 2013 ACR/ARHP Annual Meeting
Follow-Up Of Patients With Preclinical Rheumatoid Arthritis – Results Of a Telephone Survey
Pascal Klaus¹, Vivien Köhler¹, Hans Bastian¹, Tanja Braun¹, Eva Gremmelsbacher¹, Vera Höhne-Zimmer¹, Frank Buttgereit¹, Gerd Burmester¹ and Jacqueline Detert², ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany
Background/Purpose: Preclinical rheumatoid arthritis (pre-RA) describes a subset of patients with arthralgia (but no synovitis) where either anti-citrullinated peptide antibodies (ACPA) and/or rheumatoid factor (RF)…
Abstract Number: 1371 • 2013 ACR/ARHP Annual Meeting
Tuberculosis Infection In Patients With Tumor Necrosis Factor–α Antagonists In South Korea;retrospective Analysis Using By National Health Insurance Review and Assessment Service
Jong Wook Beom¹, Eun-Jung Park², Jinseok Kim³, Se Chang Park⁴ and Gi Hyeon Seo⁵, ¹Medicine, Jeju National University Hospital, Jeju, South Korea, ²Internal Medicine, Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Republic of Korea, Jeju, South Korea, ³Internal Medicine, Jeju National University Hospital, Jeju, South Korea, ⁴Veterinary Medicine, Seoul National University, Seoul, South Korea, ⁵Health Insurance Review and Assessment Service, Seoul, South Korea
Background/Purpose: Tumor necrosis factor-α (TNF-α) antagonists bring new hope for treating rheumatoid arthritis (RA) over the past decade. However, the subsequent increased risk of developing…
Abstract Number: 376 • 2013 ACR/ARHP Annual Meeting
The Risk Of Pneumococcal Infections After Immunisation With Pneumococcal Conjugate Vaccine Compared To Non-Vaccinated Inflammatory Arthritis Patients
Johanna Bengtsson¹, Pierre Geborek², Tore Saxne³, Martin Englund⁴, Ingemar F. Petersson⁴, Jan-Åke Nilsson⁵, Göran Jönsson⁶ and Meliha C. Kapetanovic⁷, ¹Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ²Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ³Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁶Lund Universoty, Dept of Clinical Sciences Lund, Section of Infectious Diseases, Lund, Sweden, ⁷Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden
The risk of pneumococcal infections after immunisation with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patientsBackground/Purpose: The purpose was to examine the risk of…
Abstract Number: 2098 • 2012 ACR/ARHP Annual Meeting
Patient Report Outcomes Variance Between Centers Is Much Lower Than Physician and Laboratory Assessed Measures of Rheumatoid Arthritis Activity: Results From a Multinational Study
Nasim A. Khan¹, Horace Spencer², Tuulikki Sokka³ and QUEST-RA⁴, ¹Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, ²University of Arkansas for Medical Sciences, Little Rock, AR, ³Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁴Jyväskylä
Background/Purpose: Clinical trials and epidemiological rheumatoid arthritis (RA) studies often recruit patients from multiple centers. We studied the proportion of variance in the American…
Abstract Number: 1288 • 2012 ACR/ARHP Annual Meeting
A Significant Number of Patients with Chronic Arthritis Received a Reduced Dosage of Biological Drugs: an Observational Study in Clinical Practice
Jose Inciarte-Mundo¹, Maria Victoria Hernández², Violeta Rosario¹, Sonia Cabrera¹, Virginia Ruiz-Esquide³, Maria Eugenia Gomez-Caballero¹, Jose A. Gómez-Puerta¹, Julio Ramirez¹, Juan D. Cañete² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: Biological agents are used to treat chronic arthritis according to the standard dosages from phase III clinical trials. However, in some patients, a good…
Abstract Number: 479 • 2012 ACR/ARHP Annual Meeting
Active Immunization with TNF-Kinoid in Rheumatoid Arthritis Patients with Secondary Resistance to Tumor Necrosis Factor-Alpha Antagonists Is Safe and Immunogenic
Patrick Durez¹, Pedro Miranda², Antoaneta Toncheva³, Alberto Berman Sr.⁴, Oscar L. Rillo⁵, Yves Boutsen⁶, Tatjana Kehler⁷, Eugenia Mociran⁸, LiAn Soto Saez⁹, Bruno Fautrel¹⁰, Xavier Mariette¹¹, Panayot Solakov¹², Eleonora Lucero¹³, Tonko Vlak¹⁴, Simeon Grazio¹⁵, Ksenija Mastrovic¹⁶, Rodica Chiriac¹⁷, Géraldine Grouard-Vogel¹⁸, Olivier Dhellin¹⁸, Stéphane Ouary¹⁸, Pierre Vandepapeliere¹⁸ and Marie-Christophe Boissier¹⁹, ¹Department of Rheumatology, Université Catholique de Louvain, Brussels, Belgium, ²Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, ³National Multiprofile Transport Hospital, Sofia, Bulgaria, ⁴Internal Medicine, Hospital Padilla, Tucuman, Argentina, ⁵Rheumatology, Hospital General de Agudos "Dr. E. Tornú", Buenos Aires, Argentina, ⁶UCL Mont-Godinne, Godinne, Belgium, ⁷Thalassotherapia Opatija, Opatija, Croatia, ⁸Emergency County Hospital Dr Constantin Opis, Maramures, Romania, ⁹Sociedad Medica del Aparato Locomotor SA, Santiago de Chile, Chile, ¹⁰Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ¹¹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹²Plovdiv, Diagnostic and Consulting Center, Plovdiv, Bulgaria, ¹³Rheumatology Unit, Padilla Hospital, Tucumán, Argentina, ¹⁴University Hospital Split, Split, Croatia, ¹⁵Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, ¹⁶Clinical Hospital Sveti Duh, Zagreb, Croatia, ¹⁷Rehabilitation clinical Hospital Iasi, Iasi, Romania, ¹⁸NEOVACS SA, Paris, France, ¹⁹Dept of Rheumatology, Hopital Avicenne, Bobigny, France
Background/Purpose: Blocking TNF alpha (TNFα) with monoclonal antibodies (mAbs) has been successful in the treatment of rheumatoid arthritis. However secondary resistances are frequent and impose…
Abstract Number: 112 • 2012 ACR/ARHP Annual Meeting
Time-Integrated Synovitis Activity Assessed by Power Doppler Ultrasound Significantly Correlates with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Methotrexate Alone but Not in Those Treated with TNF Antagonists
Kei Ikeda, Daiki Nakagomi, Yoshie Sanayama, Mieko Yamagata, Ayako Okubo, Taro Iwamoto, Hirotoshi Kawashima, Kentaro Takahashi and Hiroshi Nakajima, Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan
Background/Purpose: Although a number of studies have shown a higher sensitivity of ultrasound than clinical joint examination in detecting synovitis in patients with rheumatoid arthritis…
Abstract Number: 2099 • 2012 ACR/ARHP Annual Meeting
Patient Self-Assessments and Selected Patient Reported Outcomes May Reliably Identify Rheumatoid Disease Flare in Early Rheumatoid Arthritis Patients
Vivian P. Bykerk¹, Clifton O. Bingham III², Ernest Choy³, Juan Xiong⁴, Gilles Boire⁵, Carol A. Hitchon⁶, Janet E. Pope⁷, J. Carter Thorne⁸, Boulos Haraoui⁹, Edward Keystone¹⁰ and Susan J. Bartlett¹¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ¹⁰University of Toronto, Toronto, ON, Canada, ¹¹Clinical Epidemiology, McGill University, Montreal, QC, Canada
Background/Purpose: Significant RA worsening or flare may predict poorer outcomes and signal a need for treatment reassessment. However, there is little agreement about how to…
Abstract Number: 1293 • 2012 ACR/ARHP Annual Meeting
Importance of Steady-State Trough Concentrations After Intravenous Golimumab with Concomitant Methotrexate in Subjects with Active Rheumatoid Arthritis
J. H. Leu¹, Z. Xu¹, C. Hu¹, Alan Mendelsohn¹, J. Ford¹, Hugh M. Davis² and H. Zhou¹, ¹Janssen Research and Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To determine an optimized dosing regimen for IV golimumab in subjects with active RA using population pharmacokinetic (PK) modeling and simulation. Methods: Two Phase…
Abstract Number: 489 • 2012 ACR/ARHP Annual Meeting
The Comparative Effectiveness of Anti-TNF Medications Among Older and Disabled Rheumatoid Arthritis Patients in the U.S. Medicare Population
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell³, Lang Chen⁴, Shuo Yang⁵, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Health Care Organization & Policy, University of Alabama-Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Evaluating the real world effectiveness of biologic DMARDs in rheumatoid arthritis (RA) patients using administrative claims data has previously not been feasible due to…
Abstract Number: 114 • 2012 ACR/ARHP Annual Meeting
US Examination of Wrists and Hands: A Comparison Between Rheumatoid Arthritis and Psoriatic Arthritis
Andrea Delle Sedie¹, Elisa Cioffi¹, Linda Carli², Elena Sardano³, Stefano Bombardieri¹ and Lucrezia Riente¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Immunology Unit, University of Pisa, Immunology Unit, University of Pisa, Italy
Background/Purpose: very little is known about the differences in joint and periarticular structure involvement in rheumatoid or psoriatic arthritis (PsA). The main pathological features detected…
Abstract Number: 2074 • 2012 ACR/ARHP Annual Meeting
Combined Effects of a c-Fos/AP-1 Inhibitor T-5224 and Methotrexate On Collagen-Induced Arthritis in Mice
Tomomi Date¹, Yukihiko Aikawa¹, Tetsuya Yamamoto¹, Hirokazu Narita¹, Shuichi Hirono² and Shunichi Shiozawa³, ¹Research Laboratories, Toyama Chemical Co., Ltd, Toyama, Japan, ²Department of Pharmaceutical Sciences, School of Pharmacy, Kitasato University, Tokyo, Japan, ³Department of Medicine & Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: Activator protein-1 (AP-1) is an important transcription factor for cytokine production and joint destruction in rheumatoid arthritis (RA), and a potential target for the…
Abstract Number: 1219 • 2012 ACR/ARHP Annual Meeting
Periodontal Disease Is Associated with Rheumatoid Arthritis but Its Severity Is Not Correlated with Rheumatoid Arthritis Disease Activity
In Ah Choi¹, Jin-Hee Kim², Kyung Hwa Kim², Hye Won Kim³, Myeong Jae Yoon¹, Bon Seung Ku⁴, Hyejin Oh³, Joo Youn Lee⁵, Eun Young Lee¹, Eun Bong Lee⁶, Yong-Moo Lee² and Young Wook Song⁷, ¹Department of Internal Medicine, School of Medicine, Seoul National University, Seoul, South Korea, ²Department of Periodontology, School of Dentistry, Seoul National University, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Central Hospital, Ulsan, South Korea, ⁵Department of molecular medicine and biophamaceutical sciences,Seoul National University, Seoul, South Korea, ⁶Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁷Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, Seoul, South Korea
Background/Purpose: The prevalence of periodontal disease is known to be increased in patients with rheumatoid arthritis (RA) compared to the general population. We investigated whether…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].